Azenta (STU:BA3) ROCE %: -0.90% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BA3 Azenta Inc STU:BA3
78 GF Score
Price €28.20
GF Value €45.97
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Azenta ROCE %?

Azenta STU:BA3 -1.40% 78 ROCE % is -0.90% as of Jun. 2026. GuruFocus rates STU:BA3 with a GF Score™ of 78/100 and a GF Value™ of €45.97 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Azenta's annualized ROCE % for the quarter that ended in Jun. 2026 was -0.90%.

Azenta  (STU:BA3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Azenta ROCE % Related Terms

Azenta ROCE % Historical Data

* Premium members only.

The historical data trend for Azenta's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Azenta ROCE % Chart

Azenta Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.33 -0.99 -1.76 -1.70 -1.13

Azenta Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 0.51 -1.34 -3.56 -0.90
STU:BA3
78GF Score
Azenta Inc STU:BA3
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Azenta ROCE % Calculation

Azenta's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=-18.465/( ( (1892.339 - 185.686) + (1754.764 - 202.498) )/ 2 )
=-18.465/( (1706.653+1552.266)/ 2 )
=-18.465/1629.4595
=-1.13 %

Azenta's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-12.724/( ( (1646.864 - 222.471) + (1628.551 - 236.594) )/ 2 )
=-12.724/( ( 1424.393 + 1391.957 )/ 2 )
=-12.724/1408.175
=-0.90 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.90% mean?
Azenta (STU:BA3) has a ROCE % of -0.90% as of Jun. 2026.
Is Azenta's ROCE % too high?
Azenta's current ROCE % is -0.90%. Overall, Azenta has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Azenta's ROCE % compare to KMTS and STAA?
Azenta's ROCE % of -0.90% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 3.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 3.25, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Azenta's current ROCE % is -0.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azenta stock overvalued right now?
Based on GuruFocus' analysis, Azenta (STU:BA3) is currently considered Significantly Undervalued. The stock's GF Value™ is €45.97, compared to a current price of €28.20 — trading 38.7% below its estimated fair value. The current ROCE % is -0.90%. Azenta's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Azenta (STU:BA3), the current ROCE % is -0.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Azenta (STU:BA3) Overvalued in 2026?

Based on GuruFocus' analysis, Azenta stock appears to be undervalued. The current stock price of €28.20 is trading 38.7% below its estimated GF Value™ of €45.97. GuruFocus considers Azenta to be Significantly Undervalued.

Key valuation signals for STU:BA3:

  • ROCE %: -0.90%
  • GF Value™: €45.97 vs. price of €28.20 (38.7% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the STU:BA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Azenta Business Description

Other Exchanges AZTA:USA0HQ1:UK
Address 200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
78GF Score

Get the complete analysis for STU:BA3

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.20
Price
€45.97
GF Value